Transdermal absorptive drug formulation

Details Transdermal absorptive drug formulation Transdermal absorptive drug formulation

1994-05-10

1997-02-11

Fay, Zohreh

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514403, A61K 31415

Patent

active

056021658

ABSTRACT:
A transdermal absorptive drug formulation containing 3-isobutyryl-2-isopropylpyrazolo [1,5-a ]pyridine as active ingredient effective for bronchial asthma and cerebrovascular disorder is provided. The formulation affords excellent sustained releasing and long acting characteristics with substantially reduced side-effects such as nausea and vomitting.

REFERENCES:
patent: 4568343 (1986-02-01), Leeper et al.
patent: 5164189 (1991-05-01), Farhadieh et al.
Chem Abst, 106:436d (1987), Yoshitaka et al.
Chem Abst, 109:98852w (1988), Zupan et al.
Chem Abst, 105:18189q (1986), Sato et al.
Chem Abst, 109:215909h (1988), Bannon et al.
Chemical Abstracts, vol. 103, No. 9, 2nd Sep. 1985 p. 40, No. 64597c, Columbus Ohio, US;.
Y. Kudo et al Effect of KC-404 on experimental cerebral infarction in rats & Nippon Yakurigaku Zasshi 1985 (85(6), 435-41.

Affiliated with

Also associated with

Rating

Transdermal absorptive drug formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transdermal absorptive drug formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal absorptive drug formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-342601